MedTrace Logo

The Efficacy and Safety of Caffeic Acid for Esophageal Cancer

NCT03070262 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2020-11-27

No results posted yet for this study

Summary

Caffeic acid can target inhibit GASC1 (gene amplified in squamous cell carcinoma 1, also known as KDM4C and JMJD2C) expression and GASC1 is confirmed to be a new oncogene in several cancers including esophageal cancer. This study aims to investigate the efficiency and safety of coffeic acid in chinese advanced esophageal squamous cell cancer (ESCC).

Conditions

  • Esophagus Cancer

Interventions

DRUG

CA

caffeic acid, 300mg, tid, po

DRUG

placebo group

placebo tablet, 3 tablets, tid, po

Sponsors & Collaborators

  • Anyang Tumor Hospital

    collaborator OTHER

  • 150th Hospital of PLA

    collaborator OTHER_GOV

  • The First Affiliated Hospital of Henan University of Science and Technology

    lead OTHER

Principal Investigators

  • Shegan Gao, PhD · The Clinical Medical College, The First Affiliated Hospital of Henan Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03070262 on ClinicalTrials.gov